Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biophytis Sa ADR
(NQ:
BPTS
)
0.2900
-0.0400 (-12.12%)
Streaming Delayed Price
Updated: 12:09 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biophytis Sa ADR
< Previous
1
2
3
Next >
Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19
May 09, 2023
Via
ACCESSWIRE
Biophytis Strengthens its Management Team
May 02, 2023
Via
ACCESSWIRE
Biophytis Announces Receipt of Nasdaq Notice
April 28, 2023
Via
ACCESSWIRE
Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 19, 2023
Via
ACCESSWIRE
Biophytis Publishes its Financial Results for the First Half of 2022
January 31, 2023
Via
ACCESSWIRE
Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd
January 19, 2023
Via
ACCESSWIRE
Biophytis Announces 2022 Financial Results and 2023 Perspectives
April 18, 2023
Via
ACCESSWIRE
Biophytis: Results of the Combined General Meeting on April 17, 2023
April 18, 2023
Via
ACCESSWIRE
Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023
March 30, 2023
Via
ACCESSWIRE
Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea
March 27, 2023
Via
ACCESSWIRE
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
March 17, 2023
Via
ACCESSWIRE
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
March 09, 2023
Via
ACCESSWIRE
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
March 02, 2023
Via
ACCESSWIRE
Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19
February 27, 2023
Via
ACCESSWIRE
Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023
February 23, 2023
Via
ACCESSWIRE
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19
February 02, 2023
Via
ACCESSWIRE
Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice
January 12, 2023
Via
ACCESSWIRE
Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed
January 05, 2023
Via
ACCESSWIRE
Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure
December 01, 2022
Via
ACCESSWIRE
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
November 03, 2022
Via
ACCESSWIRE
Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones
October 31, 2022
Via
ACCESSWIRE
Biophytis Announces Receipt of Nasdaq Notice
October 26, 2022
Via
ACCESSWIRE
Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference
September 15, 2022
Via
ACCESSWIRE
The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd
September 13, 2022
Via
ACCESSWIRE
Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure
September 07, 2022
Via
ACCESSWIRE
Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million
June 30, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 30, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of...
From
Biophytis
Via
AccessWire
Topics
Bonds
Exposures
Debt Markets
Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress
June 27, 2022
PARIS, FRANCE and CAMBRIDGE, MASSACHUSETTS / ACCESSWIRE / June 27, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company...
From
Biophytis
Via
AccessWire
Biophytis: Results of the Combined General Meeting on June 21, 2022
June 22, 2022
All ordinary and extraordinary resolutions presented by the company have been adopted
From
Biophytis
Via
AccessWire
Biophytis: Convening of Another Combined General Meeting at a Later Date
June 03, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June
May 12, 2022
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 12, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.